08:48 AM EST, 11/13/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Thursday it has completed enrollment for its phase 2 open-label clinical study evaluating the safety and tolerability of investigational Zoryve cream 0.05% in infants aged three months to less than 24 months with mild to moderate atopic dermatitis.

The company said it expects to report topline results from the study in Q1 of 2026.